

**REMARKS**

Claims 2-11 are pending in the current application. Claim 11 has been amended; it is now in independent form. Claims 2-3 and 5-9 have been amended to depend directly or indirectly from elected Claim 11. Claims 1 and 12-17 directed to non-elected inventions have been cancelled. Applicants expressly reserve the right to file divisional applications to each of the non-elected inventions.

**Restrictions**

The Office Action states that the application contains patentably distinct inventions: Group I: Claims 1-10; Group II: Claim 11; Group III: Claim 12; Group IV: Claims 13-15; Group V: Claim 16; and Group VI: Claim 17.

Applicants respectfully elect, without traverse, Group II: Claim 11 for prosecution on the merits. Claims 2-10 read thereon.

Applicants note that the prior art cited by the Examiner, Alberto R. et al. "Synthesis and Properties of Boranocarbonate: A Convenient in Situ CO Source for the Aqueous Preparation of [ $^{99m}\text{Tc}(\text{OH})_3(\text{CO})_3$ ] $^+$ ", discloses  $\text{H}_3\text{BCO}$  but does not disclose radiolabelled  $\text{H}_3\text{BCO}$ .

Should any outstanding issues remain, the Examiner is encouraged to contact Applicants' undersigned representative.

Respectfully submitted:



Alice P. Bradney  
Attorney for Applicants  
Reg. No. 51,491

Date: Oct. 16, 2007  
GlaxoSmithKline Inc.  
Corporate Intellectual Property  
Five Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Tel. (919) 483-1891  
Fax: (919) 483-7988